A comparison of linear and branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to epithelial cells in vitro and in vivo
- 18 August 2003
- journal article
- research article
- Published by Springer Nature in Gene Therapy
- Vol. 10 (19) , 1654-1662
- https://doi.org/10.1038/sj.gt.3302050
Abstract
Polyethylenimine (PEI), a polycation with high ionic charge density, has recently been used as a gene therapy delivery agent. We have defined the optimal conditions for PEI-based transfection of airway epithelial cells in vitro and in vivo and used these conditions to restore Cl- channel activity in a CF mouse model. Three forms of PEI, a linear 22 kDa (ExGen 500) form and branched 25 or 50 kDa forms were evaluated. All forms of PEI significantly increased luciferase reporter gene expression compared to the liposome DCChol/DOPE in a human bronchial epithelial cell line (16HBE) irrespective of the extent of cell confluency. With subconfluent cells, gene expression was around 1000-, 200- and 25-fold higher than liposomes using linear 22, 25 and 50 kDa PEI, respectively. The transfection efficiency was reduced in confluent and polarized epithelial cells but linear 22 kDa PEI showed the smallest decrease and gave 8000-fold better transfection in polarized cells compared to liposomes. A comparison of linear 22 or 25 kDa PEI with DCChol/DOPE for airway delivery in vivo via intranasal instillation was also performed. Linear 22 kDa PEI gave significantly better luciferase reporter gene expression of 350-fold in the lung, 180-fold in the nose and 85-fold in the trachea compared to liposome. In contrast, the 25 kDa form of PEI was no better than DCChol/DOPE. Repeat dosing with linear 22 kDa PEI failed to give reporter gene delivery comparable to the initial dose. To establish that PEI can be used to deliver a physiologically relevent gene in vivo, we used it to restore Cl- secretion by CFTR gene delivery in the airways of a CF mouse model.Keywords
This publication has 28 references indexed in Scilit:
- Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosisGene Therapy, 2000
- Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene deliveryProceedings of the National Academy of Sciences, 1999
- Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trialThe Lancet, 1999
- Polyethylenimine-based intravenous delivery of transgenes to mouse lungGene Therapy, 1998
- A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd., London, EnglandHuman Gene Therapy, 1998
- Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo.Journal of Clinical Investigation, 1997
- A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosisGene Therapy, 1997
- Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosisGene Therapy, 1997
- A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.Proceedings of the National Academy of Sciences, 1995
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989